摘要
目的探讨莉芙敏治疗围绝经期综合征患者的疗效及安全性,为临床妇科疾病治疗提供参考。方法选取2017年6月～2018年5月于我院门诊治疗的围绝经期综合征患者120例为研究对象,将患者随机分为观察组和对照组,每组60例。对照组采取口服戊酸雌二醇片联合安宫黄体酮片治疗,观察组则口服莉芙敏治疗,两组均进行连续性治疗12周。对比记录两组患者治疗后3个月绝经指数(KMI)总分和促卵泡生成素(FSH)、雌二醇(E2)水平,同时观察患者不良反应发生情况,并作统计学分析。结果观察组患者治疗后KMI评分显著低于对照组,差异有统计学意义(P <0.05);观察组患者治疗前后血清FSH、E2水平与对照组比较差异无统计学意义(P> 0.05);观察组患者不良反应发生率显著低于对照组,差异有统计学意义(P <0.05)。结论莉芙敏可显著改善围绝经期综合征症状,不影响体内激素水平,安全性较好,值得临床推广使用。
Objective To explore the effect and safety of Remifemin in the treatment of perimenopausal syndrome,and provide a reference for the treatment of gynecologic diseases.Methods120cases with perimenopause syndrome in the outpatient department of our hospital in June2017to May2018were selected as the research object.The patients were randomly divided into the observation group and the control group,60cases in each group.The control group was treated with oral Estradiol valerate tablets combined with Medroxyprogesterone17-acetate tablets,the observation group was treated with Remifemin.The two groups were continuity treated for12weeks.The total scores of Kupperman menopause index(KMI)and the level of follicle stimulating hormone(FSH),estradiol(E2)of the two groups were recorded at3months after treatment,and the incidence of adverse reaction was observed and the statistical analysis was made.Results After treatment,the KMI score of the observation group was significantly lower than the control group,the difference was statistically significant(P<0.05).There were no significant differences in serum FSH and E2levels between the observation group and the control group before and after treatment(P>0.05).The incidence of adverse reactions in the observation group was significantly lower than the control group,the difference was statistically significant(P<0.05).Conclusion Remifemin can significantly improve the symptoms of perimenopausal syndrome,dose not affect hormone levels in the body,and has good safety.It is worthy of clinical application.
作者
陈菊飞
CHEN Jufei(Obstetrics and Gynecology Department,Yunfu City Maternal and Child Health Hospital of Guangdong Province,YunfuCity Maternal and Child Health Family Planning Service Center,Yunfu 527300,China)
出处
《中国医药科学》
2018年第21期57-59,119,共4页
China Medicine And Pharmacy
基金
广东省云浮市医药卫生科研立项课题(2017B28)
